Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.68 |
| ▸ | TACR2 | P21452 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 5/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858616 | 0.89 | DRD2 (0.69) | DRD2SLC6A4TACR2CCR5CYP2D6 | |
| SCHEMBL5857960 | 0.89 | DRD2 (0.54) | DRD2SLC6A4TACR2CCR5CYP2D6 | |
| SCHEMBL5860221 | 0.88 | SLC6A4 (0.53) | DRD2SLC6A4TACR2CCR5CYP2D6 | |
| SCHEMBL5858702 | 0.88 | DRD2 (0.53) | DRD2SLC6A4TACR2CCR5CYP2D6 | |
| SCHEMBL5858680 | 0.87 | DRD2 (0.52) | DRD2SLC6A4TACR2CCR5CYP2D6 | |
| SCHEMBL5860261 | 0.87 | SLC6A4 (0.52) | DRD2SLC6A4TACR2CCR5CYP2D6 | |
| SCHEMBL5858700 | 0.87 | TACR2 (0.52) | DRD2SLC6A4TACR2CCR5CYP2D6 | |
| SCHEMBL5857996 | 0.86 | SLC6A4 (0.50) | DRD2SLC6A4TACR2CCR5CYP2D6 | |
| SCHEMBL5860217 | 0.85 | DRD2 (0.50) | DRD2SLC6A4TACR2CCR5CYP2D6 | |
| SCHEMBL5857199 | 0.85 | DRD2 (0.49) | DRD2SLC6A4TACR2CCR5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989393-B2 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2006-01-24 | — | — | US | disclosed |
| US-20030119869-A1 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119869-A1 | Ccr5 modulators benzimidazoles or benzotriazoles | CCR5, CCR2, CXCR4 | DRD2 1216/4885SLC6A4 696/4885TACR2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.